Morgan Stanley Initiates Coverage on Genzyme (GENZ) with an Overweight
More News related to GENZ
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
- PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
More News related to New Coverage
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
- Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
- Stifel Nicolaus Initiates Coverage on Hudson Valley Holding (HUVL) with a Hold
- Bernstein Initiates Coverage on Hyatt Hotels (H) with an Underperform
- MKM Partners Initiates Coverage on Palm (PALM) with a Neutral
Morgan Stanley initiates coverage on Genzyme (Nasdaq: GENZ) with an Overweight rating. Price target $94.
Genzyme Corporation is a biotechnology company.
Related Categories
New CoverageStocks Mentioned
+0.28Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
